首页> 外文期刊>Antisense & Nucleic Acid Drug Development >Progress in the delivery of therapeutic oligonucleotides: Organ/cellular distribution and targeted delivery of oligonucleotides in vivo [Review]
【24h】

Progress in the delivery of therapeutic oligonucleotides: Organ/cellular distribution and targeted delivery of oligonucleotides in vivo [Review]

机译:治疗性寡核苷酸递送的进展:体内寡核苷酸的器官/细胞分布和靶向递送[综述]

获取原文
获取原文并翻译 | 示例
           

摘要

Oligonucleotide (ODN) therapy is a powerful tool for modulation of gene expression in vivo. With advances in ODN chemistry and progress in formulation development, ODNs are becoming widely acceptable drugs. This review summarizes the current status and future trend of the in vivo application of ODN therapeutics, especially antisense ODNs. Here, we review the current understanding of the tissue/organ distribution and cellular uptake of ODN drugs administered parenterally or nonparenterally to intact animals. The problems and advantages inherent in the use of different delivery methods for the treatment of particular diseases are discussed in detail. Emphasis is placed on the most widely studied ODN analogs, the phosphorothioates (PS). Lessons learned from antisense PS studies have broad implications for ODN therapeutics in general.
机译:寡核苷酸(ODN)治疗是体内调节基因表达的强大工具。随着ODN化学的进步和配方开发的进展,ODN逐渐被广泛接受。这篇综述总结了ODN疗法,特别是反义ODN的体内应用的现状和未来趋势。在这里,我们回顾了对完整动物胃肠外或非胃肠外施用的ODN药物的组织/器官分布和细胞摄取的当前了解。详细讨论了使用不同的递送方法治疗特定疾病所固有的问题和优势。重点放在研究最广泛的ODN类似物,即硫代磷酸酯(PS)。从反义PS研究中汲取的经验教训通常对ODN治疗具有广泛的意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号